Abstract:Background: The incidence of primary liver cancer is increasing year by year. In 2022 alone, more than 900000 people were diagnosed with liver cancer worldwide, with hepatocellular carcinoma (HCC) accounting for 75%-85% of cases. HCC is the most common primary liver cancer. China has the highest incidence and mortality rate of HCC in the world, and it is one of the malignant tumors that seriously threaten the health of Chinese people. The onset of liver cancer is occult, the early cases lack typical clinical symptoms, and most of the patients are already in the middle and late stage when diagnosed. Therefore, it is very important to find new markers for the early detection and diagnosis of liver cancer, improve the therapeutic effect, and improve the prognosis of patients. Protein tyrosine phosphatase non-receptor 2 (PTPN2) has been shown to be associated with colorectal cancer, triple-negative breast cancer, non-small cell lung cancer, and prostate cancer, but its biological role and function in tumors remain to be further studied. Aim: To combine the results of relevant data obtained from The Cancer Genome Atlas (TCGA) to provide the first in-depth analysis of the biological role of PTPN2 in HCC. Methods: The expression of PTPN2 in HCC was first analyzed based on the TCGA database, and the findings were then verified by immunohistochemical staining, quantitative real-time polymerase chain reaction (qRT-PCR), and immunoblotting. The value of PTPN2 in predicting the survival of patients with HCC was assessed by analyzing the relationship between PTPN2 expression in HCC tissues and clinicopathological features. Finally, the potential of PTPN2 affecting immune escape of liver cancer was evaluated by tumor immune dysfunction and exclusion and immunohistochemical staining. Results: The results of immunohistochemical staining, qRT-PCR, and immunoblotting in combination with TCGA database analysis showed that PTPN2 was highly expressed and associated with a poor prognosis in HCC patients. Kyoto Encyclopedia of Genes and Genomes enrichment analysis showed that PTPN2 was associated with various pathways, including cancer-related pathways, the Notch signaling pathway, and the MAPK signaling pathway. Gene Set Enrichment Analysis showed that PTPN2 was highly expressed in various immune-related pathways, such as the epithelial mesenchymal transition process. A risk model score based on PTPN2 showed that immune escape was significantly enhanced in the high-risk group compared with the low-risk group. Conclusion: This study investigated PTPN2 from multiple biological perspectives, revealing that PTPN2 can function as a biomarker of poor prognosis and mediate immune evasion in HCC.

Study of PTPRO level in human hepatocellular carcinoma and its correlation with gender and prognosis

Estrogen-sensitive PTPRO expression represses hepatocellular carcinoma progression by control of STAT3.

The High Expression of PTPRH is Associated with Poor Prognosis of Human Lung Adenocarcinoma

Expression of PTPRO in primary hepatic carcinoma and its clinical significance

Decreased Expression of PTPN12 Correlates with Tumor Recurrence and Poor Survival of Patients with Hepatocellular Carcinoma.

Prognostic significance of protein expressions of ribonueleotide reductase subunits RRM1, RRM2 and RRM2B in hepatocellular carcinoma

Prognostic Value of Phosphotyrosine Phosphatases in Hepatocellular Carcinoma.

Pyroptosis Related Genes Signature Predicts Prognosis and Immune Infiltration of Tumor Microenvironment in Hepatocellular Carcinoma

The Pyroptosis Related Genes Signature Predicts Prognosis and Immune Infiltration of Tumor microenvironment in Hepatocellular carcinoma

Prognostic Significance of Preoperative Serum Alpha- Fetoprotein in Hepatocellular Carcinoma and Correlation with Clinicopathological Factors: a Single-center Experience from China.

PTPROt Maintains T Cell Immunity in the Microenvironment of Hepatocellular Carcinoma.

Protein Tyrosine Phosphatase Receptor Type O Expression in the Tumor Niche Correlates with Reduced Tumor Growth, Angiogenesis, Circulating Tumor Cells and Metastasis of Breast Cancer

Expression of Estrogen Receptor in Male Hepatocellular Carcinoma and Its Clinical Significance

Clinical Value of the Expression of PTEN Gene,Progesterone Receptor and Estrogen Receptor for Predicting Biological Behaviors and Prognosis of Breast Carcinoma

Tyrosine Phosphatase PTPRO Deficiency in ERBB2-Positive Breast Cancer Contributes to Poor Prognosis and Lapatinib Resistance

Gender disparity in hepatocellular carcinoma recurrence after curative hepatectomy

PTPRO Predicts Patient Prognosis and Correlates with Immune Infiltrates in Human Clear Cell Renal Cell Carcinoma

Protein tyrosine phosphatase non-receptor II: A possible biomarker of poor prognosis and mediator of immune evasion in hepatocellular carcinoma

The Correlation Between PTEN and P27 Expression in Primary Hepatic Carcinoma

Clinical Pathology Significance of Survivin, P-Akt and Estrogen Receptor Expression in Hepatocellular Carcinoma Tissues

PTPRO Promoter Methylation is Predictive of Poorer Outcome for HER2-positive Breast Cancer: Indication for Personalized Therapy.